FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607536313> ?p ?o ?g. }

• W2607536313 endingPage "1458" @default.
• W2607536313 startingPage "1454" @default.
• W2607536313 abstract "To obtain insight into the ontogeny of mantle cell lymphoma (MCL), we assessed 206 patients from a morphological, immunohistochemical, and immunogenetic perspective. Our series included nodal (n = 151), extranodal (n = 28), and primary splenic (n = 27) MCL cases. Skewing of the immunoglobulin heavy variable (IGHV) gene repertoire was noted, with only four IGHV genes accounting for 46% of cases and approximately 70% of cases (107/154) bearing an imprint of somatic hypermutation (SHM) ranging from minimal to pronounced. Interestingly, a distinctive immunophenotypic and immunogenetic profile was identified for primary splenic MCL, which was enriched for DBA.44-positive cases (P < 0.001) and used the IGHV1-8 gene more frequently (P = 0.02) compared to nodal or extranodal cases, alluding to distinct immunopathogenetic and antigen selection processes. Expression of CD27 (considered a marker of activated B cells) was generally dissociated from SHM and was more prevalent in cases with no or minimal/borderline SHM. These findings support the idea that antigen drive is relevant for most MCL cases, although the specific antigens and the precise location of affinity maturation remain to be elucidated. Moreover, they raise the intriguing hypothesis of multiple cellular origins for MCL. To obtain insight into the ontogeny of mantle cell lymphoma (MCL), we assessed 206 patients from a morphological, immunohistochemical, and immunogenetic perspective. Our series included nodal (n = 151), extranodal (n = 28), and primary splenic (n = 27) MCL cases. Skewing of the immunoglobulin heavy variable (IGHV) gene repertoire was noted, with only four IGHV genes accounting for 46% of cases and approximately 70% of cases (107/154) bearing an imprint of somatic hypermutation (SHM) ranging from minimal to pronounced. Interestingly, a distinctive immunophenotypic and immunogenetic profile was identified for primary splenic MCL, which was enriched for DBA.44-positive cases (P < 0.001) and used the IGHV1-8 gene more frequently (P = 0.02) compared to nodal or extranodal cases, alluding to distinct immunopathogenetic and antigen selection processes. Expression of CD27 (considered a marker of activated B cells) was generally dissociated from SHM and was more prevalent in cases with no or minimal/borderline SHM. These findings support the idea that antigen drive is relevant for most MCL cases, although the specific antigens and the precise location of affinity maturation remain to be elucidated. Moreover, they raise the intriguing hypothesis of multiple cellular origins for MCL. Recent molecular and functional evidence supports antigen drive in the pathogenesis of mantle cell lymphoma (MCL).1Agathangelidis A. Hadzidimitriou A. Rosenquist R. Stamatopoulos K. Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells.Semin Cancer Biol. 2011; 21: 299-307Crossref PubMed Scopus (15) Google Scholar Indeed, MCL is characterized by pronounced immunoglobulin (IG) gene repertoire restriction, culminating in the existence of quasi-identical (stereotyped) antigen receptors,2Hadzidimitriou A. Agathangelidis A. Darzentas N. Murray F. Delfau-Larue M.H. Pedersen L.B. Lopez A.N. Dagklis A. Rombout P. Beldjord K. Kolstad A. Dreyling M.H. Anagnostopoulos A. Tsaftaris A. Mavragani-Tsipidou P. Rosenwald A. Ponzoni M. Groenen P. Ghia P. Sander B. Papadaki T. Campo E. Geisler C. Rosenquist R. Davi F. Pott C. Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? immunogenetic support from a series of 807 cases.Blood. 2011; 118: 3088-3095Crossref PubMed Scopus (133) Google Scholar almost ubiquitous expression of activation-induced cytidine deaminase,3Xochelli A. Sutton L.A. Agathangelidis A. Stalika E. Karypidou M. Marantidou F. Lopez A.N. Papadopoulos G. Supikova J. Groenen P. Boudjogra M. Sundstrom C. Ponzoni M. Francova H.S. Anagnostopoulos A. Pospisilova S. Papadaki T. Tzovaras D. Ghia P. Pott C. Davi F. Campo E. Rosenquist R. Hadzidimitriou A. Belessi C. Stamatopoulos K. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma.Am J Pathol. 2015; 185: 1740-1748Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar and some imprint of somatic hypermutation (SHM) in the clonotypic IG heavy variable (IGHV) genes of most (approximately 70%) cases, indicating antigen interactions.2Hadzidimitriou A. Agathangelidis A. Darzentas N. Murray F. Delfau-Larue M.H. Pedersen L.B. Lopez A.N. Dagklis A. Rombout P. Beldjord K. Kolstad A. Dreyling M.H. Anagnostopoulos A. Tsaftaris A. Mavragani-Tsipidou P. Rosenwald A. Ponzoni M. Groenen P. Ghia P. Sander B. Papadaki T. Campo E. Geisler C. Rosenquist R. Davi F. Pott C. Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? immunogenetic support from a series of 807 cases.Blood. 2011; 118: 3088-3095Crossref PubMed Scopus (133) Google Scholar Furthermore, both relapsed/refractory and treatment-naïve MCL patients exhibit remarkable responses to B-cell receptor signaling inhibitors, alluding to microenvironment triggering in the natural history of MCL.4Wang M.L. Rule S. Martin P. Goy A. Auer R. Kahl B.S. Jurczak W. Advani R.H. Romaguera J.E. Williams M.E. Barrientos J.C. Chmielowska E. Radford J. Stilgenbauer S. Dreyling M. Jedrzejczak W.W. Johnson P. Spurgeon S.E. Li L. Zhang L. Newberry K. Ou Z. Cheng N. Fang B. McGreivy J. Clow F. Buggy J.J. Chang B.Y. Beaupre D.M. Kunkel L.A. Blum K.A. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.N Engl J Med. 2013; 369: 507-516Crossref PubMed Scopus (1223) Google Scholar Despite the compelling evidence for an antigen-driven origin for most MCL cases, questions abound, especially in relation to whether distinct ontogenetic pathways may lead to the considerable heterogeneity observed within MCL. Herein, we sought to obtain insights into these issues through an integrated histopathological, immunophenotypic, and immunogenetic analysis of a large series of MCL patients. Two hundred six patients with MCL, diagnosed according to the 2008 World Health Organization criteria, from institutions in Greece, Italy, Spain, and Sweden, were included in the study. On the basis of the primary site of involvement, cases were assigned into three subgroups: i) nodal: 151 cases presented with nodal disease; ii) extranodal: 28 cases in whom the primary site of involvement was located at anatomical sites other than lymph nodes, spleen, or bone marrow; and iii) splenic: 27 cases with primary splenic MCL. All cases displayed a typical MCL immunophenotype and were positive for cyclin D1 expression; no case expressed CD10. The MCL cases of the present study were not systematically tested for the presence of the CCND1 translocation; that said, all cases with available fluorescence in situ hybridization data were positive for this aberration. The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee of each institution. The evaluated samples were obtained from the following tissue locations: i) nodal subgroup: lymph node biopsy specimens (n = 137) and bone marrow biopsy specimens (n = 14) from patients with nodal MCL; ii) extranodal subgroup: biopsy samples from the involved site from patients (n = 28) with extranodal MCL; and iii) splenic subgroup: splenectomy specimens (n = 17) and bone marrow biopsy specimens (n = 10) from patients with splenic MCL. All specimens were formalin fixed and paraffin embedded. Tissue samples were stained with hematoxylin and eosin for morphological evaluation. Immunophenotyping of neoplastic cells was performed as described previously (Table 1).5Papadaki T. Stamatopoulos K. Belessi C. Pouliou E. Parasi A. Douka V. Laoutaris N. Fassas A. Anagnostopoulos A. Anagnostou D. Splenic marginal-zone lymphoma: one or more entities? a histologic, immunohistochemical, and molecular study of 42 cases.Am J Surg Pathol. 2007; 31: 438-446Crossref PubMed Scopus (46) Google Scholar, 6Ponzoni M. Kanellis G. Pouliou E. Baliakas P. Scarfò L. Ferreri A.J. Doglioni C. Bikos V. Dagklis A. Anagnostopoulos A. Ghia P. Stamatopoulos K. Papadaki T. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?.Am J Surg Pathol. 2012; 36: 1609-1618Crossref PubMed Google Scholar Immunostaining for CD27, DBA.44, IRF4/MUM1, and surface IG heavy chain were centralized.Table 1List of the Antibody Panel Used in the Present Study, the Clone, Dilution, Source, and Autostainer UsedAntibodyCloneDilutionSourceDeviceCD32GV6Ready to useVentana-Roche (Basel, Switzerland)BenchMark XTCD5SP19Ready to useVentana-RocheBenchMark XTCD1056C6Ready to useVentana-RocheBenchMark XTCD20L-261:100Dako (Glostrup, Denmark)Dako Autostainer LinkCD211F81:20DakoDako Autostainer LinkCD231B12Ready to useVentana-RocheBenchMark XTCD27137B41:20Leica (Nussloch, Germany)BenchMark XTCD35RLB251:20Cell Marque (Rocklin, CA)Dako Autostainer LinkCD43MT11:20Cell MarqueDako Autostainer LinkCD79αJCB1171:10DakoDako Autostainer LinkBclII1241:20DakoDako Autostainer LinkBclVIGI191E/A81:50Cell MarqueDako Autostainer LinkCyclin D1SP4Ready to useCell MarqueBenchMark XTHairy cell leukemiaDBA441:20DakoDako Autostainer LinkIgAPolyclonal1:7500DakoBenchMark XTIgDPolyclonal1:250DakoBenchMark XTIgGPolyclonal1:7500DakoBenchMark XTIgMPolyclonal1:5000DakoBenchMark XTκPolyclonal1:7500DakoBenchMark XTλPolyclonal1:7500DakoBenchMark XTTRAP9C51:20Cell MarqueDako Autostainer LinkIRF4/MUM1Mum1p1:20DakoDako Autostainer Link Open table in a new tab PCR amplification and sequence analysis of IGHV-IGHD-IGHJ rearrangements was performed as described previously.2Hadzidimitriou A. Agathangelidis A. Darzentas N. Murray F. Delfau-Larue M.H. Pedersen L.B. Lopez A.N. Dagklis A. Rombout P. Beldjord K. Kolstad A. Dreyling M.H. Anagnostopoulos A. Tsaftaris A. Mavragani-Tsipidou P. Rosenwald A. Ponzoni M. Groenen P. Ghia P. Sander B. Papadaki T. Campo E. Geisler C. Rosenquist R. Davi F. Pott C. Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? immunogenetic support from a series of 807 cases.Blood. 2011; 118: 3088-3095Crossref PubMed Scopus (133) Google Scholar Descriptive statistics for discrete parameters included counts and frequency distributions. For quantitative variables, statistical measures included means, medians, SD, and minimum-maximum values. The significance of bivariate relationships was assessed by χ2 and t-tests. For all comparisons, a significance level of P < 0.05 was set, and all statistical analyses were performed with the statistical package, SPSS version 12.0 (SPSS, Chicago, IL). Herein, we sought to refine our understanding about the role of antigen selection in MCL ontogeny through a combined morphologic, immunohistochemical, and immunogenetic analysis. The well-recognized cytomorphological heterogeneity of MCL was evidenced using hematoxylin and eosin staining with the common variant observed in 124/185 (67%) cases, the blastoid variant in 48/185 (26%) cases, and the pleomorphic variant in 13/185 (7%) cases. No differences were observed regarding the relative frequency of the cytological variants among nodal, extranodal, or splenic MCL. In all cases, lymphoma cells were immunoreactive for CD5, CD20, CD79a, CD43, BCL2, and cyclin D1, and were consistently negative for CD23, CD10, CD3, and BCL6. Immunohistochemical analysis was extended to include: i) CD27 and IRF4 (MUM1), markers not normally detected in naïve pregerminal center (pre-GC) B cells of the inner mantle zone7Agematsu K. Memory B cells and CD27.Histol Histopathol. 2000; 15: 573-576PubMed Google Scholar, 8Tsuboi K. Iida S. Inagaki H. Kato M. Hayami Y. Hanamura I. Miura K. Harada S. Kikuchi M. Komatsu H. Banno S. Wakita A. Nakamura S. Eimoto T. Ueda R. MUM 1/IRF 4 expression as a frequent event in mature lymphoid malignancies.Leukemia. 2000; 14: 449-456Crossref PubMed Scopus (154) Google Scholar; ii) DBA.44, which is normally expressed by inner mantle zone cells and a fraction of monocytoid B cells as well as a small proportion of indolent and aggressive B-cell lymphomas (however, not by MCL)9al Saati T. Caspar S. Brousset P. Chittal S. Caveriviere P. Hounieu H. Dastugue N. Idoipe J.B. Icart J. Mazerolles C. Production of anti-B monoclonal antibodies (DBB. 42, DBA. 44, DNA. 7, and DND. 53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice.Blood. 1989; 74: 2476-2485PubMed Google Scholar; and iii) surface immunoglobulin heavy chains (SIg). The results are detailed in Supplemental Table S1 and summarized as follows: i) 104/193 (53.9%) cases were CD27+; ii) 14/158 (8.8%) cases were DBA.44+; iii) 46/83 (55.4%) cases were IRF4+; and iv) 73/103 (71%) cases were SIgM+SIgD+, 24/103 (23%) were SIgM+SIgD−, and 6 were SIgM−SigD+ or IgG+ (3% each). Of 102 cases with available data, 47 (46%) exhibited a high Ki-67 index (≥30%); as previously reported,10Hoster E. Rosenwald A. Berger F. Bernd H.W. Hartmann S. Loddenkemper C. Barth T.F. Brousse N. Pileri S. Rymkiewicz G. Kodet R. Stilgenbauer S. Forstpointner R. Thieblemont C. Hallek M. Coiffier B. Vehling-Kaiser U. Bouabdallah R. Kanz L. Pfreundschuh M. Schmidt C. Ribrag V. Hiddemann W. Unterhalt M. Kluin-Nelemans J.C. Hermine O. Dreyling M.H. Klapper W. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network.J Clin Oncol. 2016; 34: 1386-1394Crossref PubMed Scopus (215) Google Scholar blastoid and pleomorphic variants were significantly enriched for cases with Ki-67 ≥30% [23/25 (92%); and 10/10 (100%), respectively] in contrast to common variant cases [14/57 (24.5%)] (P < 0.001). Overall, these results confirm and significantly extend earlier reports regarding the immunophenotypic heterogeneity of MCL,11Gao J. Peterson L. Nelson B. Goolsby C. Chen Y.H. Immunophenotypic variations in mantle cell lymphoma.Am J Clin Pathol. 2009; 132: 699-706Crossref PubMed Scopus (74) Google Scholar while offering novel information about the expressed IG heavy chain isotype. In keeping with the literature,2Hadzidimitriou A. Agathangelidis A. Darzentas N. Murray F. Delfau-Larue M.H. Pedersen L.B. Lopez A.N. Dagklis A. Rombout P. Beldjord K. Kolstad A. Dreyling M.H. Anagnostopoulos A. Tsaftaris A. Mavragani-Tsipidou P. Rosenwald A. Ponzoni M. Groenen P. Ghia P. Sander B. Papadaki T. Campo E. Geisler C. Rosenquist R. Davi F. Pott C. Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? immunogenetic support from a series of 807 cases.Blood. 2011; 118: 3088-3095Crossref PubMed Scopus (133) Google Scholar the IGHV gene repertoire of the present cohort was remarkably biased, with IGHV3-21 predominating [21/154 cases with available data (13.6%)], followed by the IGHV4-34 [19/154 (12.3%)], IGHV3-23 [16/154 (10.4%)], and IGHV1-8 [15/154 (9.7%)] genes. For the assessment of SHM, all cases bearing differences from the germline, even a single-nucleotide change, were considered as somatically hypermutated. Our decision to follow this strategy rather than adopt the 2% cutoff for germline identity used for prognostication purposes in chronic lymphocytic leukemia12Damle R.N. Wasil T. Fais F. Ghiotto F. Valetto A. Allen S.L. Buchbinder A. Budman D. Dittmar K. Kolitz J. Lichtman S.M. Schulman P. Vinciguerra V.P. Rai K.R. Ferrarini M. Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood. 1999; 94: 1840-1847Crossref PubMed Google Scholar, 13Hamblin T.J. Davis Z. Gardiner A. Oscier D.G. Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Blood. 1999; 94: 1848-1854Crossref PubMed Google Scholar is based on ample evidence from studies on various B-cell clones (normal, autoreactive, and malignant) that even minimal changes introduced by SHM can have an important functional impact and, thus, are biologically relevant.14Murray F. Darzentas N. Hadzidimitriou A. Tobin G. Boudjogra M. Scielzo C. Laoutaris N. Karlsson K. Baran-Marzsak F. Tsaftaris A. Moreno C. Anagnostopoulos A. Caligaris-Cappio F. Vaur D. Ouzounis C. Belessi C. Ghia P. Davi F. Rosenquist R. Stamatopoulos K. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.Blood. 2008; 111: 1524-1533Crossref PubMed Scopus (261) Google Scholar On these grounds, we considered separately 47/154 (30.6%) cases with 100% germline identity (truly unmutated) from cases bearing nucleotide changes [mutated, 107/154 (69.4%)]. The latter exhibited a variable load of SHM ranging from minimal to pronounced. More specifically, following our previous definitions,1Agathangelidis A. Hadzidimitriou A. Rosenquist R. Stamatopoulos K. Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells.Semin Cancer Biol. 2011; 21: 299-307Crossref PubMed Scopus (15) Google Scholar, 2Hadzidimitriou A. Agathangelidis A. Darzentas N. Murray F. Delfau-Larue M.H. Pedersen L.B. Lopez A.N. Dagklis A. Rombout P. Beldjord K. Kolstad A. Dreyling M.H. Anagnostopoulos A. Tsaftaris A. Mavragani-Tsipidou P. Rosenwald A. Ponzoni M. Groenen P. Ghia P. Sander B. Papadaki T. Campo E. Geisler C. Rosenquist R. Davi F. Pott C. Stamatopoulos K. Is there a role for antigen selection in mantle cell lymphoma? immunogenetic support from a series of 807 cases.Blood. 2011; 118: 3088-3095Crossref PubMed Scopus (133) Google Scholar 87/154 (56.5%) cases carried IGHV genes with 97% to 99.9% germline identity and were assigned to a borderline/minimally mutated subgroup, whereas 20/154 (12.9%) cases carried IGHV genes with <97% germline identity and were assigned to a highly mutated subgroup. Combined assessment of morphological, immunohistochemical, and immunogenetic results revealed considerable differences between nodal, extranodal, and splenic MCL, as follows. i) No primary splenic MCL case tested (n = 6) displayed high (≥30%) Ki-67 proliferation index, which was in contrast to 54.5% (42/77) of nodal and 57.8% (11/19) of extranodal MCL cases (P = 0.03). ii) DBA.44, a marker of the normal inner mantle zone cells in the lymph nodes, was not detected in any of the 18 extranodal MCL cases analyzed, was rare in nodal MCL [7/118 (5.9%)], whereas, notably, it was highly expressed among primary splenic MCL [7/22 (31.8%); P < 0.001 for both comparisons] (Figure 1). The latter is noteworthy given that DBA.44 is also expressed in the great majority of primary splenic lymphomas of postulated marginal zone origin, although not by normal splenic marginal zone cells.5Papadaki T. Stamatopoulos K. Belessi C. Pouliou E. Parasi A. Douka V. Laoutaris N. Fassas A. Anagnostopoulos A. Anagnostou D. Splenic marginal-zone lymphoma: one or more entities? a histologic, immunohistochemical, and molecular study of 42 cases.Am J Surg Pathol. 2007; 31: 438-446Crossref PubMed Scopus (46) Google Scholar iii) CD27 expression was more prevalent among cases with minimal/borderline SHM load [50/83 (60%)] or no SHM [21/43 (48.8%)], whereas it was less frequent among cases with a pronounced SHM load [6/19 (31.6%); P = 0.02 when compared to minimal/borderline SHM cases] (Figure 2). The comparison between cases with no SHM and those with pronounced SHM did not suggest a statistically significant difference (P = 0.2); however, the absolute difference in percentages was large (17.2%), leading to the assumption that the absence of significance is mainly because of the small size of the available samples (43 and 19, respectively). iv) IGHV gene usage was unevenly distributed depending on the primary site of involvement, with statistically important differences evidenced for IGHV1-8 (expressed by 27.7% of primary splenic cases versus only 7.6% and 5.2% of nodal and extranodal cases, respectively; P = 0.02), alluding to the potential role of distinct microenvironmental influences in the ontogeny of MCL.Figure 2Images from two cases within our cohort exhibiting different CD27 expression. A: Case 40 (lymph node–nodal subgroup): Strong and uniform expression of CD27 by lymphoma cells. This case was truly unmutated [germline identity (GI), 100%]. Inset: Cyclin D1 expression. B: Case 117 (bone marrow–nodal subgroup): CD27-negative lymphoma cells. This case was assigned to the heavily mutated group (GI, 96%). Inset: Cyclin D1 expression. Original magnification: ×400 (A and B); ×200 (insets).View Large Image Figure ViewerDownload Hi-res image Download (PPT) In the present study, we confirm the existence of distinct phenotypical and molecular profiles in MCL, arguing against a single cell of origin for MCL. Moreover, we document that a sizable fraction of MCL cases bearing minimal or no SHM often express CD27, a marker of activated lymphocytes, whereas, in contrast, a fraction of MCL cases with a pronounced SHM burden were negative for CD27. This novel finding of a dissociation between SHM status and CD27 expression may be considered as evidence for the operation of alternative (CD27-unrelated) modes of activation for at least some MCL progenitors, akin to what has been reported previously for other B-cell malignancies.5Papadaki T. Stamatopoulos K. Belessi C. Pouliou E. Parasi A. Douka V. Laoutaris N. Fassas A. Anagnostopoulos A. Anagnostou D. Splenic marginal-zone lymphoma: one or more entities? a histologic, immunohistochemical, and molecular study of 42 cases.Am J Surg Pathol. 2007; 31: 438-446Crossref PubMed Scopus (46) Google Scholar We also report, for the first time, that splenic MCL cases are enriched for DBA.44-positive cases and show an IGHV1-8 biased gene usage, thus exhibiting immunogenetic and immunophenotypic characteristics distinct from nodal and extranodal MCL and suggesting particular microenvironmental influences in MCL ontogeny. The clinical implications of these observations remain to be elucidated; however, it is relevant to mention that primary splenic MCL has been reported to follow a more indolent course compared to nodal MCL.15Angelopoulou M.K. Siakantariz M.P. Vassilakopoulos T.P. Kontopidou F.N. Rassidakis G.Z. Dimopoulou M.N. Kittas C. Pangalis G.A. The splenic form of mantle cell lymphoma.Eur J Haematol. 2002; 68: 12-21Crossref PubMed Scopus (47) Google Scholar, 16Navarro A. Clot G. Royo C. Jares P. Hadzidimitriou A. Agathangelidis A. Bikos V. Darzentas N. Papadaki T. Salaverria I. Pinyol M. Puig X. Palomero J. Vegliante M.C. Amador V. Martinez-Trillos A. Stefancikova L. Wiestner A. Wilson W. Pott C. Calasanz M.J. Trim N. Erber W. Sander B. Ott G. Rosenwald A. Colomer D. Gine E. Siebert R. Lopez-Guillermo A. Stamatopoulos K. Bea S. Campo E. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.Cancer Res. 2012; 72: 5307-5316Crossref PubMed Scopus (194) Google Scholar Taken collectively, our findings raise the following possibilities regarding MCL ontogeny and candidate progenitor cells. i) Naïve, pre-GC cells seem plausible progenitors for a minor fraction of MCL cases with unswitched IGs, no SHM, and negative for CD27 [8/61 (13.1%) of the cases in the present series]. In contrast, ii) bona fide memory B cells17Victora G.D. Nussenzweig M.C. Germinal centers.Annu Rev Immunol. 2012; 30: 429-457Crossref PubMed Scopus (1353) Google Scholar may represent the cell of origin for the rare MCL cases that express switched IG receptors [3/103 (2.9%) of the cases in the present series]. iii) Moving to IG borderline/minimally mutated, IgM+IgD+CD27− MCL cases, these could originate from a normal B-cell subpopulation intermediate between naïve and GC cells, with a low impact of SHM, and an IgM+IgD+CD27−CD23−CD5+CD10− phenotype.18Kolar G.R. Mehta D. Pelayo R. Capra J.D. A novel human B cell subpopulation representing the initial germinal center population to express AID.Blood. 2007; 109: 2545-2552Crossref PubMed Scopus (45) Google Scholar More complex scenarios could pertain to iv) IG-unmutated or borderline/minimally mutated, IgM+IgD+CD27+ MCL cases, which might be derived from B cells maturing in GC-independent but T-cell–dependent pathways, that have been shown to express CD27 and carry limited SHM within their IG receptor genes19Kaji T. Ishige A. Hikida M. Taka J. Hijikata A. Kubo M. Nagashima T. Takahashi Y. Kurosaki T. Okada M. Ohara O. Rajewsky K. Takemori T. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory.J Exp Med. 2012; 209: 2079-2097Crossref PubMed Scopus (196) Google Scholar; or, less plausibly, splenic marginal zone cells that display similar immunophenotypic features.20Weller S. Mamani-Matsuda M. Picard C. Cordier C. Lecoeuche D. Gauthier F. Weill J.C. Reynaud C.A. Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants.J Exp Med. 2008; 205: 1331-1342Crossref PubMed Scopus (123) Google Scholar Finally, v) IgM+IgD+ MCL cases with a substantial SHM load might originate from B cells participating in early phases of GC reactions, before class switching.21De Silva N.S. Klein U. Dynamics of B cells in germinal centres.Nat Rev Immunol. 2015; 15: 137-148Crossref PubMed Scopus (593) Google Scholar However, this one-to-one matching of MCL subgroups with distinct profiles to particular normal B-cell subpopulations most probably represents an oversimplification, especially given that the transformation process per se may induce aberrant immunophenotypes.22Gualco G. Weiss L.M. Harrington Jr., W.J. Bacchi C.E. BCL6, MUM1, and CD10 expression in mantle cell lymphoma.Appl Immunohistochem Mol Morphol. 2010; 18: 103-108Crossref PubMed Scopus (42) Google Scholar In conclusion, on the evidence presented herein, MCL appears as a remarkably heterogeneous disease where different microenvironments, immune pathways, and antigen selection processes, as well as potentially distinct cellular origins, may underlie the development of cases with unique characteristics. E.Po., A.X., and G.K. conducted research and wrote the article; E.S., L.-A.S, A.N., A.Ag., K.D., A.An., E.Pa., P.K., C.S., P.G., M.P., B.S., E.C., R.R., and A.H. provided data; K.S. and T.P. designed the study and wrote the article, which was approved by all of the authors; K.S. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Download .docx (.03 MB) Help with docx files Supplemental Table S1" @default.
• W2607536313 created "2017-05-05" @default.
• W2607536313 creator A5002784304 @default.
• W2607536313 creator A5008694656 @default.
• W2607536313 creator A5016760892 @default.
• W2607536313 creator A5018345688 @default.
• W2607536313 creator A5018989565 @default.
• W2607536313 creator A5019232305 @default.
• W2607536313 creator A5020505190 @default.
• W2607536313 creator A5023652883 @default.
• W2607536313 creator A5023804098 @default.
• W2607536313 creator A5029161067 @default.
• W2607536313 creator A5029235110 @default.
• W2607536313 creator A5032199021 @default.
• W2607536313 creator A5044130307 @default.
• W2607536313 creator A5048081963 @default.
• W2607536313 creator A5051340130 @default.
• W2607536313 creator A5059626875 @default.
• W2607536313 creator A5066430010 @default.
• W2607536313 creator A5087781912 @default.
• W2607536313 creator A5088561496 @default.
• W2607536313 creator A5090615083 @default.
• W2607536313 date "2017-07-01" @default.
• W2607536313 modified "2023-10-03" @default.
• W2607536313 title "Numerous Ontogenetic Roads to Mantle Cell Lymphoma" @default.
• W2607536313 cites W121918294 @default.
• W2607536313 cites W1243376384 @default.
• W2607536313 cites W1429374962 @default.
• W2607536313 cites W1986293452 @default.
• W2607536313 cites W2042642145 @default.
• W2607536313 cites W2042746633 @default.
• W2607536313 cites W2058421453 @default.
• W2607536313 cites W2062581231 @default.
• W2607536313 cites W2067341631 @default.
• W2607536313 cites W2090225614 @default.
• W2607536313 cites W2096672814 @default.
• W2607536313 cites W2101727960 @default.
• W2607536313 cites W2122048891 @default.
• W2607536313 cites W2129509656 @default.
• W2607536313 cites W2130672368 @default.
• W2607536313 cites W2132600682 @default.
• W2607536313 cites W2136006589 @default.
• W2607536313 cites W2154066874 @default.
• W2607536313 cites W2289178667 @default.
• W2607536313 cites W2330706961 @default.
• W2607536313 cites W4246504300 @default.
• W2607536313 doi "https://doi.org/10.1016/j.ajpath.2017.02.017" @default.
• W2607536313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28457696" @default.
• W2607536313 hasPublicationYear "2017" @default.
• W2607536313 type Work @default.
• W2607536313 sameAs 2607536313 @default.
• W2607536313 citedByCount "11" @default.
• W2607536313 countsByYear W26075363132017 @default.
• W2607536313 countsByYear W26075363132018 @default.
• W2607536313 countsByYear W26075363132019 @default.
• W2607536313 countsByYear W26075363132020 @default.
• W2607536313 countsByYear W26075363132021 @default.
• W2607536313 countsByYear W26075363132022 @default.
• W2607536313 countsByYear W26075363132023 @default.
• W2607536313 crossrefType "journal-article" @default.
• W2607536313 hasAuthorship W2607536313A5002784304 @default.
• W2607536313 hasAuthorship W2607536313A5008694656 @default.
• W2607536313 hasAuthorship W2607536313A5016760892 @default.
• W2607536313 hasAuthorship W2607536313A5018345688 @default.
• W2607536313 hasAuthorship W2607536313A5018989565 @default.
• W2607536313 hasAuthorship W2607536313A5019232305 @default.
• W2607536313 hasAuthorship W2607536313A5020505190 @default.
• W2607536313 hasAuthorship W2607536313A5023652883 @default.
• W2607536313 hasAuthorship W2607536313A5023804098 @default.
• W2607536313 hasAuthorship W2607536313A5029161067 @default.
• W2607536313 hasAuthorship W2607536313A5029235110 @default.
• W2607536313 hasAuthorship W2607536313A5032199021 @default.
• W2607536313 hasAuthorship W2607536313A5044130307 @default.
• W2607536313 hasAuthorship W2607536313A5048081963 @default.
• W2607536313 hasAuthorship W2607536313A5051340130 @default.
• W2607536313 hasAuthorship W2607536313A5059626875 @default.
• W2607536313 hasAuthorship W2607536313A5066430010 @default.
• W2607536313 hasAuthorship W2607536313A5087781912 @default.
• W2607536313 hasAuthorship W2607536313A5088561496 @default.
• W2607536313 hasAuthorship W2607536313A5090615083 @default.
• W2607536313 hasBestOaLocation W26075363131 @default.
• W2607536313 hasConcept C142724271 @default.
• W2607536313 hasConcept C151730666 @default.
• W2607536313 hasConcept C203014093 @default.
• W2607536313 hasConcept C2777525834 @default.
• W2607536313 hasConcept C2779338263 @default.
• W2607536313 hasConcept C37291498 @default.
• W2607536313 hasConcept C54355233 @default.
• W2607536313 hasConcept C67236022 @default.
• W2607536313 hasConcept C71924100 @default.
• W2607536313 hasConcept C78458016 @default.
• W2607536313 hasConcept C86803240 @default.
• W2607536313 hasConceptScore W2607536313C142724271 @default.
• W2607536313 hasConceptScore W2607536313C151730666 @default.
• W2607536313 hasConceptScore W2607536313C203014093 @default.
• W2607536313 hasConceptScore W2607536313C2777525834 @default.
• W2607536313 hasConceptScore W2607536313C2779338263 @default.
• W2607536313 hasConceptScore W2607536313C37291498 @default.

• next